Boosting for international pipeline!Nanjing Transthera completed Round D financing of about US $100 million!

Recently, Transthera (Nanjing) Technology Co., Ltd. (hereinafter referred to as "Transthera") in NJBPV of Jiangbei New Area announced that it had completed Round D financing of about US $100 million. This round of financing is jointly led by CITICPE Private Equity Funds Management Co., Ltd. and China State-owned Enterprise Structural Adjustment Fund Co.,Ltd. Sixty Degree capital, China Merchants Capital, Shanghai Jinpu Health Care Equity Investment Fund, Costone Capital and Jiangsu WinFast(Ruihua) Holding follow-up investment, including the original shareholders. The funds raised in this round will be used to continue to promote the international development of pipeline projects under research. China Renaissance (“CR”) acted as the exclusive financial advisor for this round of financing.

Dr. Frank Wu (Wu Yongqian), President and CEO of Transthera makes the statement: "it is a great honor and I would like to extend sincere gratitude to the new and old shareholders for their trust and support. Transthera will continue to take the mission of truly solving the unmet clinical needs in the world, and research and develop new small molecule drugs in the world. This round of financing will help us continue the global development of innovative drug pipelines and achieve our strategic objectives of internationalization and commercialization. "